Health
“A clinical trial found that high-dose vitamin C (75g, 3x weekly) added to chemotherapy for stage 4 pancreatic cancer cut cancer death by more than 50%, with median overall survival of 16 months in the ascorbate group versus 8.3 months in the standard-of-care group (p=0.030)." Post caption: "Those taking the vitamin C in addition to chemo…”
Plain restatementA randomized trial in stage IV pancreatic cancer reported longer median overall survival (16 vs 8.3 months) and longer median progression free survival (6.2 vs 3.9 months) when 75 g of ascorbate three times weekly was added to gemcitabine plus nab-paclitaxel, with a hazard ratio for death of 0.46 and p = 0.030.
General information only - not medical advice.
The study is real and the numbers are quoted correctly. A randomized phase 2 trial from the University of Iowa, published in Redox Biology in 2024, found median overall survival of 16 months versus 8.3 months when high-dose vitamin C was added to standard chemotherapy for stage 4 pancreatic cancer, with p = 0.030. The crucial missing word is intravenous. The patients received 75 grams infused into a vein three times a week, which raises blood vitamin C levels around 500-fold to a range that swallowing vitamin C cannot reach at any dose, so this result says nothing about oral vitamin C supplements. The claim also leaves out that only 34 patients were analyzed, that the trial was stopped early because the early results looked strong, which tends to make effects look bigger than they are, and that the researchers used a less strict statistical threshold than confirmatory trials use. The phrase "cut cancer death by more than 50%" comes from a hazard ratio of 0.46 and describes a slower rate of death over time, not half as many people dying. The study authors themselves say the trial is small, lacks diversity, and is meant to help design a larger phase 3 trial, which has not yet reported.
A [drifted from the evidence:] clinical trial [drifted from the evidence:] found that high-dose vitamin C (75g, 3x weekly) added to chemotherapy for stage [drifted from the evidence:] 4 pancreatic cancer [drifted from the evidence:] cut cancer death by more than 50%, with median overall survival [drifted from the evidence:] of 16 [drifted from the evidence:] months in the ascorbate group versus 8.3 months [drifted from the evidence:] in the standard-of-care group (p=0.030)." Post caption: "Those taking the vitamin C in addition to chemo had improved: Overall survival, Progression free survival. [drifted from the evidence:] Over the next few years.
A [added by the neutral restatement:] randomized trial [added by the neutral restatement:] in stage [added by the neutral restatement:] IV pancreatic cancer [added by the neutral restatement:] reported longer median overall survival (16 [added by the neutral restatement:] vs 8.3 months) [added by the neutral restatement:] and longer median progression free survival [added by the neutral restatement:] (6.2 vs 3.9 months) when 75 g of ascorbate three times weekly was added to gemcitabine plus nab-paclitaxel, with a hazard ratio for death of 0.46 and p = 0.030.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The study exists and is correctly cited. Redox Biology 77 (2024) 103375, Bodeker et al., is a real peer-reviewed paper, and the image in the post is its genuine Figure 3.
- Median overall survival of 16 months (ascorbate) versus 8.3 months (standard of care) is quoted exactly as published.
- p = 0.030 for overall survival is quoted exactly as published.
- The progression free survival figures in the post's image text (6.2 vs 3.9 months, p = 0.029) are also quoted exactly.
- The dose and schedule, 75 g three times weekly, is correct.
- It was a randomized trial in stage IV pancreatic cancer, and the vitamin C was added to chemotherapy rather than replacing it. The post states this correctly.
- The reported hazard ratio for death was 0.46, so "more than 50%" is a defensible arithmetic reading of that point estimate (a 54% lower hazard).
- The trial reported no increase in frequency or severity of adverse events from adding ascorbate.
- Omitted qualifier, the single most important one: the claim as circulated says "high-dose vitamin C (75g, 3x weekly)" and never says intravenous. The intervention was a 75 g intravenous infusion. The authors' own data show IV raised plasma ascorbate roughly 500-fold to millimolar levels, which oral dosing cannot reach at any dose. Placing this next to a call to action about "supplement deep dives" invites readers to map the result onto oral vitamin C products, where the proposed mechanism does not apply.
- Exaggeration via hazard-ratio restatement: "cut cancer death by more than 50%" reads as if half the deaths were prevented. A hazard ratio of 0.46 describes a lower rate of death per unit time over the follow-up period, not half as many patients dying. In metastatic pancreatic cancer, deaths in both arms were near-universal; what changed was timing. The published median gain was about 7.7 months.
- Omitted qualifier: the trial analyzed 34 patients. The claim presents a two-arm result of roughly 17 patients per arm as if it were a settled finding.
- Omitted qualifier: the trial was stopped early for apparent benefit, which systematically inflates observed effect sizes.
- Omitted qualifier: significance was assessed with one-sided testing at the 0.05 level with 90% confidence intervals, not the conventional two-sided 95% standard, and the OS confidence interval upper bound of 0.92 is close to no effect.
- Omitted qualifier: the authors explicitly position this as effect-size data to design a phase 3 trial, not as evidence of established effectiveness. The claim drops that framing entirely.
- Temporal overreach in the caption: "over the next few years" overstates follow-up. The medians are 16 and 8.3 months on data frozen December 2023.
- Context omission: the comparison arm's progression free survival (3.9 months) ran shorter than in MPACT, the trial that established the gemcitabine plus nab-paclitaxel regimen, which the authors note and which widens the apparent gap.
- Whether the effect replicates. No completed phase 3 confirmatory trial of pharmacological ascorbate in metastatic pancreatic cancer was found in searching. The authors call for one.
- The precise degree to which early stopping inflated the point estimate cannot be quantified from the published summary.
- Per-arm patient numbers, baseline covariate balance, and the supplementary multivariable Cox adjustment were referenced in the paper but not retrieved in full detail here, so the robustness of the estimate to baseline imbalance is not independently assessed in this report.
- Whether the original poster stated "intravenous" anywhere in the video or caption text not captured at intake. The recorded caption and overlay text do not contain it.
The study is real, the figure in the post is the real Figure 3, and the numbers quoted are exact. The paper reports that patients diagnosed with stage IV pancreatic cancer were randomized 1:1 to gemcitabine and nab-paclitaxel only (SOC, control) or to SOC with concomitant P-AscH-, 75 g three times weekly (ASC, investigational), and that P-AscH- added to gemcitabine plus nab-paclitaxel increased overall survival to 16 months compared to 8.3 months (HR = 0.46; 90 % CI 0.23, 0.92; p = 0.030). Median progression free survival was 6.2 (ASC) versus 3.9 months (SOC) (HR = 0.43; 90 % CI 0.20, 0.92; p = 0.029), and adding P-AscH- did not negatively impact quality of life or increase the frequency or severity of adverse events. Scale and status of the trial: thirty-six participants were randomized; of these 34 received their assigned study treatment, and at the time of the interim analysis thirty-six participants had been randomized across two academic sites, with participants evaluable if one dose of assigned treatment was received, resulting in an analysis cohort of 34. The reported survival benefit was strong enough that researchers stopped the trial early, a point the institution's own spokesperson confirms: "The results were so strong in showing the benefit of this therapy for patient survival that we were able to stop the trial early." The route of administration is central and is stated by the authors throughout. The abstract defines the agent as "Pharmacological ascorbate (P-AscH-, high dose, intravenous, vitamin C)", and the paper reports that intravenous administration of P-AscH- resulted in a nearly 500-fold increase in plasma ascorbate levels, with average concentration 16 plus or minus 3 mM in the ASC cohort compared to 0.034 plus or minus 0.02 mM in the SOC cohort. The trial registry specifies that the ascorbate is administered intravenously, through a vein in the arm. The authors themselves frame the result as hypothesis-generating rather than practice-changing: "Although limited by small sample size and a lack of diversity, this randomized, actively controlled trial provides key data regarding effect size to design a phase 3 trial to assess effectiveness of P-AscH- with metastatic PDAC as well as its generalizability to a larger population."
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Is this a real study, and are the numbers accurate?
Yes. It is a real randomized trial published in Redox Biology in 2024, and the figures quoted, 16 months versus 8.3 months median overall survival with p=0.030, match the published paper exactly.
What is the most important thing the claim leaves out?
The claim never mentions that the vitamin C was given intravenously. The trial used a 75 gram IV infusion that raised blood ascorbate levels roughly 500-fold, a level oral vitamin C supplements cannot reach at any dose.
Does 'cut cancer death by more than 50%' mean half the patients survived who otherwise wouldn't have?
No. That phrase comes from a hazard ratio of 0.46, which describes a slower rate of death over time, not half as many deaths. The actual gain in median survival was about 7.7 months, and deaths occurred in nearly all patients in both groups.
How many patients were in this trial, and does that matter?
Only 34 patients were analyzed, split between two arms. The trial was also stopped early because the results looked strong, which tends to make effects appear larger than they would in a bigger, longer study.
Does this mean vitamin C is now a proven treatment for pancreatic cancer?
No. The study authors themselves describe it as a small trial meant to help design a larger phase 3 trial, not as proof of effectiveness. The case file notes that no completed phase 3 confirmatory trial was found.